MoneyWorks4Me

Sandu Pharmaceutical - Quaterly Results

14 Feb 2024 Evaluate
The quarter ended December 2023 witnessed marginal change in the total revenue. The figure for the mentioned quarter is pegged at Rs. 174.29 millions.Profit after Tax for the quarter ended December 2023 saw a decline of -57.35% from Rs. 4.83 millions to Rs. 2.06  millions.Operating profit for the quarter ended December 2023 decreased to 5.37 millions as compared to 8.47 millions of corresponding quarter ended December 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 174.29 170.92 1.97 516.93 500.84 3.21 653.49 655.00 -0.23
Other Income 0.27 0.28 -3.57 1.15 2.83 -59.36 3.27 0.83 293.98
PBIDT 5.37 8.47 -36.60 18.06 22.89 -21.10 28.16 29.57 -4.77
Interest 0.18 0.19 -5.26 0.56 0.64 -12.50 0.80 1.10 -27.27
PBDT 5.19 8.28 -37.32 17.50 22.25 -21.35 27.36 28.47 -3.90
Depreciation 1.42 1.28 10.94 3.97 3.82 3.93 5.17 5.30 -2.45
PBT 3.77 7.00 -46.14 13.53 18.43 -26.59 22.19 23.17 -4.23
TAX 1.71 2.17 -21.20 4.86 5.91 -17.77 6.97 7.27 -4.13
Deferred Tax 0.64 0.22 190.91 1.10 0.32 243.75 0.34 0.31 9.68
PAT 2.06 4.83 -57.35 8.67 12.52 -30.75 15.22 15.90 -4.28
Equity 96.61 96.61 0.00 96.61 96.61 0.00 96.61 88.11 9.65
PBIDTM(%) 3.08 4.96 -37.82 3.49 4.57 -23.56 4.31 4.51 -4.55
Peers
Company Name CMP
Sun Pharma. Inds. 1820.00
Dr. Reddys Labs. 1236.00
Cipla 1350.00
Lupin 2042.00
Zydus Lifesciences 1163.35
View more..